|1.||Skakkebaek, Niels E: 10 articles (09/2015 - 01/2003)|
|2.||Rajpert-De Meyts, Ewa: 9 articles (09/2015 - 01/2003)|
|3.||Skakkebaek, N E: 8 articles (02/2012 - 05/2001)|
|4.||Ghovanloo, Maysam: 6 articles (01/2015 - 01/2010)|
|5.||Sharpe, Richard M: 6 articles (10/2010 - 07/2003)|
|6.||Jørgensen, Niels: 5 articles (06/2013 - 01/2003)|
|7.||Toppari, J: 5 articles (02/2012 - 07/2005)|
|8.||Main, K M: 5 articles (04/2010 - 05/2001)|
|9.||Main, Katharina M: 4 articles (09/2015 - 10/2009)|
|10.||Kim, Jeonghee: 4 articles (01/2015 - 07/2012)|
07/01/2012 - "Patients (age 15-50) with deep hip or groin pain (n=202) and controls (n=20) wore an accelerometer that recorded TDS. "
04/01/2008 - "The risk of TDS > 16 was odds ratio (OR) = .2 (95% CI: .1 to .3) comparing children with the most and least severe functional limitations; OR = 3.2 (95%CI: 2.1 to 4.8) comparing children with IQ < 70 and others; OR = 2.7 (95% CI: 1.5 to 4.6) comparing children in severe pain and others; OR = 2.7 (95% CI:1.6 to 4.6) comparing children with another disabled sibling or OR = 1.8 (95%CI: 1.2 to 2.8) no siblings and others; OR = 1.8 (95% CI: 1.1 to 2.8) comparing children resident in a town and others. "
04/01/2008 - "Better gross motor function, poorer intellect, more pain, having a disabled or ill sibling and living in a town were independently associated with TDS > 16. "
02/01/2006 - "The VRS and VAS results show that TDS beta significantly decreased pain score compared to placebo (p < 0.02). "
01/01/2003 - "The aim of this review was to assess the efficacy and tolerability of this transdermal system (TDS) in patients with chronic pain. "
01/01/2014 - "The purpose of the current study was to benchmark ex vivo the sensitivity of GC tumor cells from patients to standard cytotoxic and some newly introduced targeted drugs (TDs), as a basis for drug selection in the treatment of GC. "
07/01/2015 - "Both methods had significantly better sensitivity than Karlsson's criteria (sensitivity 31.8%, p<0.05) and endometrial thickness (sensitivity 47.7%, p<0.05), and better specificity than tumor/uterine volume ratio (specificity 28.3%, p<0.05) and TDS (specificity 41.5%, p<0.05). "
07/01/2015 - "Endometrial thickness, tumor/uterine 3D volume ratio, tumor distance to myometrial serosa (TDS), and van Holsbeke's subjective model were assessed retrospectively. "
01/01/2015 - "We classified the TDs into two groups: invasive-type TD (iTD), which is characterized by the presence of lymphatic invasion, vascular invasion, perineural invasion, or undefined cancer cell clusters and nodular-type TD (nTD), which is characterized by a smooth or irregular-shaped tumor nodule other than an iTD. "
01/01/2015 - "We showed that the average number of tumor nodules interpreted as LNs per case and the number of cases with positive LNs were significantly decreased with the seventh edition compared with fifth/sixth; however, numbers of cases with TDs and <12 LNs were significantly increased with the seventh edition compared with fifth/sixth. "
|3.||Postoperative Nausea and Vomiting (PONV)
06/01/2009 - "A statistically significant reduction in postoperative nausea between 8 and 24 hours in patients receiving TDS was noted. "
11/01/2010 - "The aim of this study was to explore the efficacy and tolerability of TDS in the prevention of PONV in adults. "
11/01/2010 - "TDS appeared to be effective compared with placebo in the prevention of postoperative nausea when treatment was initiated the night before (early application) (RR = 0.56; 95% CI, 0.41-0.75; P < 0.001) or on the day of surgery (late application) (RR = 0.61; 95% CI, 0.47-0.79; P < 0.001). "
11/01/2010 - "In the postanesthesia care unit, TDS was associated with a significantly reduced risk for postoperative nausea compared with placebo (relative risk [RR] = 0.77; 95% CI, 0.61-0.98; P = 0.03). "
11/01/2010 - "TDS is a centrally acting anticholinergic agent that was approved in 2001 by the US Food and Drug Administration for the prevention of postoperative nausea and vomiting (PONV). "
01/01/2001 - "This randomized, multicentre, double-blind, double-dummy study compared the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in 395 patients with a clinical diagnosis of acute exacerbation of chronic bronchitis (AECB). "
01/01/2001 - "Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis."
01/01/1989 - "Amoxycillin 500 mg tds and cefadroxil 1 g bd were equally effective in the treatment of acute exacerbations of chronic bronchitis."
12/01/1997 - "A prospective, multicentre, randomized, open-label, parallel group study compared the efficacy, safety and tolerability of cefuroxime 750 mg iv administered either twice daily (bd) or three times daily (tds) for 48-72 h, followed by oral cefuroxime axetil 500 mg bd for 5-7 days in a sequential therapy regimen for the treatment of acute exacerbations of chronic bronchitis. "
07/01/1991 - "Fifty-one patients admitted to hospital with severe exacerbations of chronic bronchitis entered a double-blind trial of treatment with cefaclor (500 mg tds) compared with amoxycillin (500 mg tds) for 7 days. "
|5.||Stomach Ulcer (Gastric Ulcer)
12/01/1989 - "The efficacy of ranitidine (150 mg nocte), and sucralfate (1 g tds) as maintenance therapy to prevent gastric ulcer relapse was evaluated in a 12 month trial in 363 patients. "
05/01/1993 - "This study compared the frequency of healing of gastric ulcers treated with either ranitidine 300 mg nocte plus sucralfate 1 g tds or with ranitidine 300 mg nocte plus placebo. "
|5.||Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)
|1.||Drug Therapy (Chemotherapy)
|3.||Intensive Care (Surgical Intensive Care)
|4.||Body Piercing (Piercing, Body)
|5.||Self-Help Devices (Assistive Technology)